Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954534 | 1.00 | CA2 (0.46) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL2952253 | 1.00 | CA2 (0.46) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL29205059 | 0.94 | CA2 (0.41) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL29205057 | 0.94 | CA2 (0.41) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL29205058 | 0.94 | CA2 (0.41) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL23430580 | 0.87 | EPHX1 (0.56) | CA2GPR84BIRC2LCKPPARD | |
| SCHEMBL6550164 | 0.85 | HDAC7 (0.54) | CA2CA1 | |
| SCHEMBL20535411 | 0.84 | CA2 (0.47) | CA2GPR84FFAR1BIRC2LCK | |
| SCHEMBL2896967 | 0.83 | MAPT (0.47) | CA2GPR84FFAR1BIRC2 | |
| SCHEMBL29205062 | 0.83 | GPR84 (0.42) | GPR84FFAR1LCKPPARDZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | CA2 722/4885GPR84 1469/4885FFAR1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.